Launches
Sandoz’s aflibercept biosimilar Enzeevu launch in Canada comes just a few days after the firm signed a multiple asset deal, including an undisclosed ophthalmology product, with Alvotech, which recently gained immediate launch for its Eylea rival in the country.
Just a few days after Alvotech announced global settlements for its Eylea rival, Samsung Bioepis has followed up with its own agreements with the originators.
Bristol Myers Squibb execs David Elkins and Adam Lenkowsky spoke with Scrip about the company’s efforts to grow new products and advance novel drugs before Opdivo and Eliquis lose exclusivity in 2028.
Alvotech has ticked off all of the remaining patent-related matters for its aflibercept biosimilar, with multiple market entries expected in 2026.
As Dr Reddy’s delivered results for its financial third quarter, the firm revealed a slew of updates for key biosimilars in its pipeline including filing and launch plans for abatacept in the US and Europe, as well as US setbacks on rituximab and denosumab.
BMS will continue to seek legal recourse even as Zydus Lifesciences launches the world’s first cut-price nivolumab biosimilar in India following a Delhi High Court division bench ruling in favor of the Indian company.
BMS tells Scrip it will continue to seek legal recourse even as Zydus Lifesciences launches the world’s first cut-price nivolumab biosimilar in India following a Delhi High Court division bench ruling in favor of the Indian company
Hikma has launched its Enoby and Xtrenbo denosumab biosimilars to Amgen’s Prolia and Xgeva into the competitive US market. How will the firm fare against so many other rivals?
European CNS specialist rolls out a value-added methylphenidate and a first-to-market guanfacine generic as it sharpens its European ADHD strategy.
Civica kept its promise to market its insulin glargine and Stelara biosimilars at the start of the new year.
2025 saw star products debut in India as foreign firms doubled down on high-value, IP-protected therapies. Experts tell Scrip the top 10 cities in the country can now sustain “US/EU-style” specialty launches.
Alvotech and marketing partner Advanz Pharma have claimed a first with the launch of their Gobivaz golimumab biosimilar rival to Simponi in Europe.